help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Delmas, P. D.
Right arrow Articles by Meunier, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Delmas, P. D.
Right arrow Articles by Meunier, P. J.

Journal of Clinical Endocrinology & Metabolism, Vol 54, 837-844, Copyright © 1982 by Endocrine Society

ARTICLES

Long term effects of dichloromethylene diphosphonate in Paget's disease of bone

PD Delmas, MC Chapuy, E Vignon, S Charhon, D Briancon, C Alexandre, C Edouard and PJ Meunier

Dichloromethylene diphosphonate (Cl2MDP) is a diphosphonate which markedly inhibits bone resorption. We have tested Cl2MDP in Paget's disease, a disorder characterized by increased bone remodeling. Sixty- three patients with progressive Paget's disease were treated for 6 months with Cl2MDP at daily oral doses of 400, 800, 1600, or 2400 mg. Thirty-nine patients received calcium and vitamin D supplements during treatment. patients in all treatment groups had significant reduction in serum alkaline phosphatase, urinary hydroxyproline, skeletal uptake of 99mtechnetium-diphosphonate scintiscans, and resorption parameters on iliac crest biopsy samples as assessed by quantitative histomorphometry. Treatment was well tolerated and did not induce a skeletal mineralization defect. The reduction in alkaline phosphatase and urinary hydroxyproline persisted 1 yr after withdrawal of treatment. The biochemical remission was sustained in half of the patients 2 yr after the end of treatment and was accompanied by a marked reduction of bone pain. a daily dose of 800 mg is recommended as the best of control of clinical and biochemical symptoms. The transient increase in iPTH levels observed in patients treated with Cl2MDP alone did not occur when calcium and vitamin D were added. We conclude that Cl2MDP is effective in the treatment of Paget's disease of bone and provides a prolonged response. Dietary supplementation with calcium and vitamin D is desirable to prevent secondary hyperparathyroidism.


This article has been cited by other articles:


Home page
 Cancer Res.Home page
P. Fournier, S. Boissier, S. Filleur, J. Guglielmi, F. Cabon, M. Colombel, and P. Clezardin
Bisphosphonates Inhibit Angiogenesis in Vitro and Testosterone-stimulated Vascular Regrowth in the Ventral Prostate in Castrated Rats
Cancer Res., November 15, 2002; 62(22): 6538 - 6544.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. R. Singer, T. L. Clemens, R. A. Eusebio, and P. J. Bekker
Risedronate, a Highly Effective Oral Agent in the Treatment of Patients with Severe Paget's Disease
J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 1906 - 1910.
[Abstract] [Full Text]

Home page
 NEJMHome page
P. D. Delmas and P. J. Meunier
The Management of Paget's Disease of Bone
N. Engl. J. Med., February 20, 1997; 336(8): 558 - 566.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1982 by The Endocrine Society